The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery

Cancer Journal from Scientific American

Volumn 4, Issue 2, 1998, Pages 110-124

  Dahlborg, Suellen A ^a   Petrillo, Annie ^a   Crossen, John R ^b   Roman Goldstein, Simon ^a   Doolittle, Nancy D ^a   Fuller, Kristi H ^b   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Carboplatin; CNS lymphoma; Cognitive function; Cyclophosphamide; Etoposide; Germ cell tumor; Methotrexate; Neuropsychological assessment; Primitive neuroectodermal tumor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; PROCARBAZINE; SODIUM THIOSULFATE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; BRAIN HERNIA; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DRUG DELIVERY SYSTEM; DRUG RESPONSE; FEMALE; FEVER; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROECTODERM TUMOR; OTOTOXICITY; PRIORITY JOURNAL; SEPSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DIURETICS, OSMOTIC; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; INFANT; INJECTIONS, INTRA-ARTERIAL; LYMPHOMA; MALE; MANNITOL; METHOTREXATE; NEUROECTODERMAL TUMORS, PRIMITIVE; NEUROPSYCHOLOGICAL TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032464432     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Albright LA. Pediatric brain tumors. CA Cancer J Clin 1993;43: 272-288.
2. Pollack IF. Brain tumors in children. N Engl J Med 1994;331: 1500-1507.
3. Crossen JR, Garwood D, Glatstein E et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-642.
4. Frytak S, Shaw JN, O'Neill BP. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989;12:27-33.
5. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A et al: Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst 1990;6:60-65.
6. Meadows AT, Gordon J, Massari DJ et al. Decline in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukemia treated with cranial irradiation. Lancet 1981;181:1015-1018.
7. Silverman CL, Palkes H, Talent B et al. Late effects of radiotherapy on patients with cerebellar medulloblastoma. Cancer 1984;54: 825-829.
8. Ris MD, Noll RB. Long-term neurobehavioral ourcome in pediatric brain-tumor patients: review and methodological critique. J Clin Exp Neuropsych 1994;16:21-42.
9. Balmaceda D, Heller G, Rosenblum M et al. Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. J Clin Oncol 1996;14:2908-2915.
10. A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models. In: Blasberg RG, Groothuis D, Molnar P et al, eds. Pathophysiology of the Blood-Brain Barrier. New York: Elsevier, 1991:197-220.
11. Groothuis DR, Fischer JM, Lapin G. Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol 1982;41:164-185.
12. Neuwelt EA, Dahlborg SA. Blood-brain barrier disruption in the treatment of brain tumors: clinical implications. In: Neuwelt EA, ed. Implications of the Blood-Brain Barrier and Its Manipulation: Clinical Implications. New York: Plenum, 1989:195-262.
13. Posner JB. Management of central nervous system metastases. Semin Oncol 1977;4:81-91.
14. Rosner D, Nemoto T, Pickren J et al. Management of brain metastases from breast cancer by combination chemotherapy. J Neurooncol 1983;1:131-137.
15. Tator CH. Chemotherapy of brain tumors: uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice. J Neurosurg 1972;37:1-8.
16. Finlay JL, Goldman S, Wong MC et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 1996;14:2495-2503.
17. Bonstelle CT, Kori SH, Rekate H. Intracarotid chemotherapy of glioblastoma after induced blood-brain barrier disruption. Am J Neuroradiol 1983;4:810-812.
18. Chiras J, Dormont D, Fauchon F et al. Intra-arterial chemotherapy of malignant gliomas. J Neuroradiol 1988;15:31-48.
19. Fauchon F, Chiras J, Poisson M et al. Intra-arterial chemotherapy by cisplatin and cytrabine after temporary disruption of the blood-brain barrier for the treatment of malignant gliomas in adults. J Neuroradiol 1986;13:151-162.
20. Gumerlock MK, Belshe BD, Madsen R et al: Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncology 1992;12:33-46.
21. Li V, Levin AB, Turski P. Intra-arterial chemotherapy following blood-brain barrier disruption in patients with recurrent high grade astrocytomas. Proc Am Assoc Neurol Surg 1988; abstr 404.
22. Markowsky SK, Zimmerman CL, Tholl D et al. Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monk 1991;13:24-31.
23. Miyagami M, Tsubokawa T, Taxoe M et al. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir (Tokyo) 1990;30:582-590.
24. Miyagami M, Kagawa Y, Tsubokawa T. ACNU delivery to malignant glioma tissue by osmotic blood-brain barrier modification with Intracarotid infusion of hyperosmolar mannitol. No Shinkei Geka 1985;13:955-963.
25. Neuwelt E, Goldman D, Dahlborg S et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-1590.
26. Sata S, Toya S, Otani M. Blood-brain barrier opening microcirculation in human brain tumor. Brain Nerve (Japan) 1985;37: 109-113.
27. Sato S, Yoshinori A, Kodama R. Blood-brain barrier opening microcirculation in human brain tumor. Prog Comput Tomogr (Japan) 1985;7:43-48.
28. Yamada K, Takahama H, Nakai O et al. Intra-arterial chemotherapy for malignant glioma after osmotic blood-brain barrier disruption. Jpn J Cancer Chemother 1989;16:2692-2696.
29. Packer RJ, Ater J, Allen J et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747-754.
30. Neuwelt EA, Goldman D, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-1590.
31. Neuwelt EA, Frenkel EP, Gumerlock MK et al. Developments in the diagnosis and treatment of primary CNS lymphoma: a prospective series. Cancer 1986;58:1609-1020.
32. Macdonald DR, Cascino TL, Schold SC et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
33. Williams JA, Roman-Goldstein S, Crossen JR et al. Preirradiation osmotic blood-brain barrier disruption plus combination chemotherapy in gliomas: quantitation of tumor response to assess chemosensitivity. In: Drewes LR, Betz AL, eds. Frontiers in cerebral vascular biology: transport and its regulation. New York: Plenum, 1993:273-284.
34. Williams PC, Henner WD, Roman-Goldstein S et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37:17-28.
35. Crossen JR, Goldman D, Dahlborg SA et al. Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 1992;30:23-29.
36. Dahlborg SA, Henner WD, Crossen JR et al. Non-AIDS primary CNS lymphoma: the first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 1996;2: 166-174.
37. Roman-Goldstein S, Mitchell P, Crossen JR et al. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Am J Neuroradiol 1995; 16:543-553.
38. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: Research Edition. San Antonio, Texas: The Psychological Corporation, 1987.
39. Jastak S, Jastak GS. Wide Range Achievement Test - Revised. Wilmington, Delaware: Jastak Associates Inc., 1984.
40. Wechsler D. Wechsler Memory Scale - Revised. San Antonio, Texas: The Psychological Corporation, 1987.
41. Wechsler D. Wechsler Adult Intelligence Scale - Revised. San Antonio, Texas: The Psychological Corporation, 1987.
42. Woodcock RW, Johnson MB. Woodcock-Johnson Psycho-educational Battery - Revised. Allen, Texas: DLM Teaching Resources, 1990.
43. Bornstein RA. Normative data on selected neuropsychological measures from a nonclinical sample. J Clin Psychol 1985;41:651-659.
44. Klonoff H, Low M. Disordered brain function in young children and early adolescents: Neuropsychological and electroencephalographic correlates. In: Reitan RM, Darison LA, eds. Clinical Neuropsychology: Current Status and Applications. Washington, DC: VH Winson & Sons, 1974.
45. Spreen O, Strauss ME, eds. A Compendium of Neuropsychological Tests. New York: Oxford University Press, 1991.
46. Kolb B, Whishaw IQ, eds. Fundamentals of Human Neuropsychology. New York: Freeman, 1985.
47. Chiulli SJ, Yeo RA, Haaland KY et al. Complex figure copy and recall in the elderly. J Clin Exp Neuropsychol 1989;11:95 (abstr).
48. Jennings MT, Gelman R, Hochberg FH. Intracranial germ cell tumors: natural history and pathogenesis. In: Neuwelt EA, ed. The Diagnosis and Treatment of Pineal Region Tumors. Baltimore: Williams & Wilkins, 1984;116-138.
49. Calaminus G, Bamberg M, Baranzelli MC et al. Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics 1994;25:26-32.
50. Neuwelt E, Howieson J, Frenkel E et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-582.
51. Hoffman HJ, Otsubo H, Hendrick EB et al. Intracranial germ-cell rumors in children. J Neurosurg 1991;74:545-551.
52. Allen JC, Kim JH, Packer RJ. Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg 1987;67:65-70.
53. Miller DC, Hochberg FH, Harris NL et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. Cancer 1994;74:1383-1397.
54. Neuwelt EA, Williams PC, Mickey BE et al. Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr Neurosurg 1994;21:16-22.
55. Freilich RJ, Delattre JY, Monjour A et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-439.
56. Stewart DJ, Russell N, Dennery J et al. Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma. Biology of Brain Tumour 1986; 2:433-436.
57. Packer RJ, Sutton LN, DeAngelis G et al. Management of children with primitive neuroectodermal tumors of the posterior fossa/ medulloblastoma. Pediatr Neurosci 1986;12:272-282.
58. Hart MN, Earle KM. Primitive neuroectodermal tumors of the brain in children. Cancer 1973;32:890-897.
59. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1-15.
60. Rorke LB, Gilles FH, Davis RL et al. Revision of World Health Organization classification of brain tumors for childhood brain tumors. Cancer 1985;56:1869-1886.
61. Hughes EN, Shillito J, Sallan SE et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984: the influence of radiation dose on the patterns of failure and survival. Cancer 1988;61:1992-1998.
62. Krischer JP, Ragab AH, Kun L et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:905-909.
63. Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990;28:823-828.
64. Packer RJ, Sutton LN, Alderman R et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCU, and vincristine chemotherapy. J Neurosurg 1994;81:690-698.
65. Cohen BH, Zeltezer PM, Boyett JM et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Children's Cancer Group randomized trial. J Clin Oncol 1995;13:1687-1696.
66. Gajjar A, Mulhern RK, Heideman RL et al. Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin Oncol 1994;12:1212-1216.
67. Mosijczuk AD, Nigro MA, Thomas PRM et al. Preradiation chemotherapy in advanced medulloblastoma: a pediatric oncology group pilot study. Cancer 1993;72:2755-2762.
68. Packer RJ, Sutton LN, Goldwein JL et al. Role of chemotherapy in the management of childhood medulloblastoma/primitive neuroectodermal tumor. In: Packer RJ, ed. Anonymous Advances in Chemotherapy. 1996:161-175.
69. Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma: results of prospective randomized trial of radiation therapy with and without CCU, vincristine and prednisone. J Neurosurg 1990;72:572-582.
70. Garton GR, Schomberg PJ, Scheithauer BW et al. Medulloblastoma - prognostic factors and outcome of treatment: review of the Mayo Clinic experience. Mayo Clin Proc 1990;65:1077-1086.
71. Halberg RE, Wara WM, Fippin LF et al: Low-dose craniospinal radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 1991;20:651-654.
72. Roberts RO, Lynch CF, Jones MP et al. Medulloblastoma: a population-based study of 532 cases. J Neuropathol 1991;50: 134-144.
73. Cohen B, Packer RJ, Siegel KR et al. Brain tumors in children under 2 years: treatment, survival and long-term prognosis. Pediatr Neurosurg 1993;19:171-179.
74. Geyer JR, Zeltzer PM, Boyette JM et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in one day: a report from the Children's Cancer Group. J Clin Oncol 1994;12:1607-1615.
75. Jooma R, Hayward RD, Grant DN. Intracranial neoplasms during the first year of life: analysis of one hundred cases. Neurosurgery 1984;14:31-41.
76. Tomita T, McLone D. Brain tumors during the first twenty-four months of life. Neurosurgery 1985;17:913-919.
77. Burstein S. Growth disorders after cranial radiation in childhood (editorial). J Clin Endocrinol Metab 1994;78:1280-1281.
78. DeLatt CA, Lampkin BC. Long-term survivors of childhood cancer: evaluation and identification of sequelae of treatment. CA Cancer J Clin 1992;42:263-282.
79. Goldwein JW, Radcliffe J, Johnson J et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiation Oncol Biol Phys 1996;43: 899-904.
80. Johnson DL, McCabe MA, Nicholson S et al. Quality of long-term survival in young children with medulloblastoma. J Neurosurg 1994;80:1004-1010.
81. Kun L, Mulhern RK, Crisco JJ. Quality of life in children treated for brain tumors: intellectual, emotional, and academic function. J Neurosurg 1983;58:1-6.
82. Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390-1396.
83. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328: 1725-1731.
84. Dupuis-Girod S, Hartmann O, Benhamen E et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplement cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncology 1996;27:87-98.
85. Neuwelt, EA, Brummett RE, Remsen LG et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 1996;56:706-709.
86. Johnson BE, Patronas N, Hayes W et al. Neurologic, computed cranial tomographic and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6-to 13-year survivors. J Clin Oncol 1990;8:48-56.
87. Mahler P, Griffin B, Geyer JR et al. Chemoradiotherapy interactions and the blood-brain barrier, In: Neuwelt EA, ed. Implications of the Blood-Brain Barrier and Its Manipulation. New York: Plenum, 1989;373-387.
88. Bleyer WA. Hobson's choice in CNS prophylaxis of small cell lung cancer. Int J Radiat Oncol Biol Phys 1988;14:783-785.
89. Remsen LG, McCormick CI, Sexton G et al. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence. Clin Cancer Res 1995;1:731-739.